ducovest

ESL:F:F-EssilorLuxottica Société anonyme (EUR)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 245.5

Change

+2.00 (+0.82)%

Market Cap

USD 118.76B

Volume

226.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

EssilorLuxottica Société anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in North America, the Middle East, Africa, Europe, Latin America, and the Asia-Pacific. It offers lens, eyewear, contact lenses, reading glasses under the Essilor, Varilux, Crizal, Eyezen, Stellest, Xperio, Transitions, Ray-Ban, Oakley, Barberini, KODAK Lens, Nikon, Shamir, eyexpert, iWear, Humanware, Optifog, Persol, Oliver Peoples, Vogue Eyewear, Arnette, Alain Mikli, Costa, Bliz, Native Eyewear and Bolon, and Foster Grant brands. The company also provides vision assessment, eye pathology diagnosis and treatment, finishing equipment, fitting parameter measurement, small tools, and consumables. In addition, it offers SPECTRALIS, a multimodal imaging platform for the diagnosis and treatment; ANTERION, a multi-disciplinary all-in-one anterior segment imaging solution for measurements; HEYEX 2, an image management and device integration platform; HEYEX EMR, an electronic medical record platform; digital surgical visualization platform; and high-tech equipment for optical surfacing, polishing, measuring, coating, and finishing, as well as consumables, tools, and services under the Satisloh brand. Further, the company designs, develops, markets, and maintains lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. It sells its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and consumers through the network of brick and mortar retail network and its online channels. The company was formerly known as Essilor International Société Anonyme and changed its name to EssilorLuxottica Société anonyme in October 2018. EssilorLuxottica Société anonyme was founded in 1849 and is headquartered in Paris, France.

Company Website : https://www.essilorluxottica.com

Currency: EUR

Country : Germany

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-05 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
IUI1:F Intuitive Surgical Inc

+0.65 (+0.13%)

 USD 180.46B
ESLC:F ESSILORLUXOTTICA 1/2/O.N.

N/A

 USD 112.84B
BOX:F Becton Dickinson and Company

+0.15 (+0.10%)

 USD 43.29B
HYB0:F HOYA CORP. ADR/ 1 O.N.

-0.50 (-0.50%)

 USD 37.66B
HYB:F HOYA Corporation

-1.25 (-1.22%)

 USD 37.63B
RME:F ResMed Inc

+1.50 (+0.69%)

 USD 32.97B
RMEA:F Resmed Inc DRC

+0.20 (+0.93%)

 USD 31.15B
56S0:F RENAU.UNSP.ARD 1/5 EO-20

+0.30 (+1.62%)

 USD 20.06B
56S1:F Sartorius Stedim Biotech SA

+0.30 (+0.16%)

 USD 19.82B
CBH:F COLOPLAST SP.ADR 1/10 DK1

+0.05 (+0.62%)

 USD 19.20B

ETFs Containing ESL:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.60% 76% C+ 64% D
Dividend Return 1.68% 80% B- 46% F
Total Return 6.28% 76% C+ 64% D
Trailing 12 Months  
Capital Gain 18.31% 79% B- 75% C
Dividend Return 1.90% 44% F 22% F
Total Return 20.22% 73% C 69% C-
Trailing 5 Years  
Capital Gain 101.19% 94% A 81% B-
Dividend Return 13.01% 65% D 24% F
Total Return 114.20% 89% A- 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 18.51% 89% A- 81% B-
Dividend Return 19.64% 81% B- 73% C
Total Return 1.13% 58% F 32% F
Risk Return Profile  
Volatility (Standard Deviation) 18.38% 72% C 72% C
Risk Adjusted Return 106.85% 99% N/A 95% A
Market Capitalization 118.76B 99% N/A 98% N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.